Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Lumacaftor Monotherapy and Lumacaftor + Ivacaftor in Cystic Fibrosis with F508del-CFTR
2010-020413-90Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Lumacaftor monotherapy, Lumacaftor + Kalydeco and Placebo (3 arms). Primary endpoints: Safety and tolerability of lumacaftor monotherapy and lumacaftor + ivacaftor, Efficacy of lumacaftor monotherapy and lumacaftor + ivacaftor and 2 more. Started Oct 2010; status: completed.
02
Drugs
ivacaftorlumacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-020413-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020413-90.